Tranexamic acid is a synthetic derivative of the amino acid lysine.Tranexamic acid (commonly marketed in tablet form as Lysteda and in IV form as Cyklokapron in the U.S.and as Transamin,Transcam in Asia, and Espercil in South America) is often prescribed for excessive bleeding.

Tranexamic acid is an antifibrinolytic that competitively inhibits the activation of plasminogen to plasmin, a molecule
responsible for the degradation of fibrin. Fibrin is the basic framework for the formation of a blood clot in
hemostasis.Tranexamic acid has roughly 8 times the antifibrinolytic activity of an older analogue, ε-aminocaproic acid.

Tranexamic acid is frequently used in surgeries with high risk of blood loss such as cardiac, liver, vascular and large orthopedic procedures. Its oral form is now being evaluated for use in outpatient conditions involving heavy bleeding.
Trauma Tranexamic acid has been found to decrease the risk of death in people who have significant bleeding due to trauma. However, it may actually increase the risk of death due to bleeding if administered more than 3 hours after the injury.